Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes. Continue reading
Utilizing autologous [the patient’s own]stem cells to regenerate heart muscle, scientists at the Novant Health Group have successfully treated patients that suffered from severe heart attacks; potentially limiting the long term loss of tissue and preserving heart function for victims. The patient’s own mesenchymal stem cells [the same type as dental stem cells] are harvested and then implanted back into the damaged area, where they recruit surrounding cells to aid in the repair process. Continue reading
A year long clinical trial by the University of Miami Miller School of Medicine has demonstrated that autologous [the patient’s own] mesenchymal stem cells (the type of stem cells found in teeth) are a safe and effective stem cell source for regenerative therapies for the treatment of Ischemic Cardiomyopathy. The study also determined that mesenchymal stem cell treatment was more effective than treatments utilizing bone marrow mononuclear cells. Continue reading
Researchers Dr. Luis Gruberg and Dr. Allen Jeremias, from the Stony Brook Heart Institute and Intensive Care Unit, have conducted a clinical study utilizing the patient’s own stem cells to treat them after suffering a severe heart attack. The treatement, which involves infusing millions of autologous [the patient’s own] stem cells into the coronary artery, successfully regenerated damaged tissue in the heart. Continue reading
Researchers all around the world are working towards utilizing stem cells to grow replacement organs. While once thought to be a futuristic concept, it is now very real. Doctors and researchers have successfully transplanted lab grown bladders, blood vessels, tear ducts, arteries and windpipes. Now, research teams around the world are growing urethras, bile ducts, larynxes, bones, livers, kidneys, and even hearts.
Mesoblast, a leading stem cell technology and regenerative therapeutics company, received FDA approval to begin a Phase III clinical trial utilizing their stem cell therapy [Revascor] to treat heart failure. We have reported on Mesoblast in previous posts; most recently, the announcement that they were developing neural related regenerative therapies utilizing dental pulp stem cells.
In a recent Phase I clinical study, a collaboration of the Cedars-Sinai Heart Institute, the EMMES Corporation and Johns Hopkins University, researchers sought to regenerate heart tissue that is functionally compromised and typically scarred as a result of a heart attack. More specifically, the treatment involves the extraction of the stem cells from the patients, the in vitro [in the lab] expansion of the stem cells and the transplantation of the stem cells back into the patient. The success of this early stage study should lead the way to larger larger studies.